Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01524575
Recruitment Status : Withdrawn (the trial was never opened and then withdrawn permanently)
First Posted : February 2, 2012
Last Update Posted : September 25, 2019
Information provided by (Responsible Party):
University of Hawaii

No Study Results Posted on for this Study
Study was withdrawn before participants were enrolled.
Recruitment Status : Withdrawn
Estimated Primary Completion Date : July 2013
Estimated Study Completion Date : January 2014